Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer
#A 83-01 ; #9094360 ; **** BioGems 제품이나 Peprotech 으로 표기 Cancers (Basel). 2024 Apr 17;16(8):1532. Sainab Totonji 1, Anna Ramos-Triguero 1, Dominica Willmann 1, Manuela Sum 1, Sylvia Urban 1, Helena Bauer 1, Astrid Rieder 1, Sheng Wang 1, Holger Greschik 1, Eric Metzger 1 2, Roland Schüle 1 2 3 Affiliations expand Abstract Novel treatment modalities are imperative for the challenging management of muscle-invasive and metastatic BC to improve patient survival rates. The recently identified KMT9, an obligate …
Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer 더 보기 »